Phenytoin Sodium

Phase 3Small molecule

FFood and Drug Administration (FDA)

Phenytoin Sodium is one of 53 small molecule programs targeting Brain Injury. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain InjuryNot yet recruiting

Brain InjuryPhase 3

Not yet recruiting

Competition

Competitive Landscape

64 competitors in Brain Injury

#DrugCompanyPhaseTrials

Ritalin

Novartis

Approved

4 2

Keppra

UCB

Approved

4 3

Namenda

AbbVie

Approved

3 4

Buspar

Bristol-Myers Squibb

Approved

2 5

Celexa

AbbVie

Approved

2 6

Vimpat

UCB

Approved

2 7

Rozerem

Takeda

Approved

1 8

Vyvanse

Takeda

Approved

1 9

Exelon

Novartis

Approved

1 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Not yet recruiting

Brain Injury

NCT04573803

Clinical

Trials by Indication[1]

Epilepsy1 trial

Characterization of Epilepsy Patients BEEP 2b

Completed·FFood and Drug Administration (FDA)·Phase 1·NCT02707965·21 enrolled

Brain Injury1 trial

Pharmacological Management of Seizures Post Traumatic Brain Injury

Not yet recruiting·—·Phase 3·NCT04573803·1,649 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Phenytoin Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Phenytoin Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Phenytoin Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Food and Drug Administration (FDA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFood and Drug Administration (FDA)

Phenytoin Sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Epilepsy1 trial

Brain Injury1 trial

References

Drug Info

Quick Facts

Related News